Overview

In this video, Dr. Naiem T. Issa reviews long-term data from the ADvocate
1, ADvocate 2, and ADjoin studies, highlighting sustained skin clearance
(EASI 90/100), stable monthly maintenance responses, and durable itch
relief with Ebglyss® (lebrikizumab) 250 mg Q4W for up to 3 years in
moderate-to-severe atopic dermatitis. He also shares a real-world case of a
77-year-old patient with longstanding atopic dermatitis, demonstrating
marked improvements in BSA and itch severity after 20 weeks of
lebrikizumab monotherapy, reinforcing its depth and durability of response.

This Class for

Clinical Pharmacy
Pharmacy
Physician
Resident / Fellow

What I will learn?

• Review up to 3-year efficacy data of lebrikizumab 250 mg Q4W, including
sustained EASI 90/100 responses.
• Highlight the stability of skin clearance and itch improvement with monthly
maintenance dosing.
• Demonstrate real-world effectiveness through a patient case showing
improvements in BSA and Itch NRS.
• Reinforce the key message that lebrikizumab delivers deep and durable
control of moderate-to-severe atopic dermatitis.

Disclaimer

This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
(This information/content is intended to Health Care Providers only)

For adverse events and safety reporting: email: [email protected]

24 /7 mobile: +966 567 868 843, Working hours Tel: +966 11 461 7800 , Ext: 1

For Lilly product information: email: [email protected]

For further information, please contact:

Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: [email protected]

PP-LK-SA-0264

Content